Estradiol and progesterone receptors in breast cancer: prognostic value after relapse.
The prognostic significance of estradiol (ER) and progesterone receptors (PgR) for survival from relapse has been studied in two groups of breast cancer patients: group 1, 35 patients in whom receptor levels were measured at the time of mastectomy; group II, 49 patients in whom receptor levels were measured at the time of recurrence. ER+ (greater than 10 fmoles/mg) patients had a better survival from relapse than ER- patients. High levels of PgR (greater than 50 fmoles/mg) had a prognostic significance only in group II patients.
D000328:Adult; D000368:Aged; D001943:Breast Neoplasms / Q000032:analysis* / Q000401:mortality; D005260:Female; D006801:Humans; D008408:Mastectomy; D008593:Menopause; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local; D011379:Prognosis; D011959:Receptors, Estradiol / Q000032:analysis*; D011960:Receptors, Estrogen / Q000032:analysis*; D011980:Receptors, Progesterone / Q000032:analysis*; D012878:Skin Neoplasms / Q000556:secondary
D011959:Receptors, Estradiol; D011960:Receptors, Estrogen; D011980:Receptors, Progesterone